Chapter 25 / Rescue, Crisis, Inspection, and Leadership Judgment / Paid beta preview

Chapter 25: Leadership When the Room Is Divided

How to lead divided rooms through decision rights, dissent, risk acceptance, and execution. ## When The Facts Do Not Decide For You RESP-640 had become clearer and harder at the same time. The team knew more than it had known in Chapter 21. The safety signal had been escalated. Follow-up was active. Protocol drift had been documented. Amendment options existed. Regulatory and ethics communication were moving through the right owners. The inspection-readiness story was no longer guesswork. But the facts did not decide the next step by themselves. Medical recommended a temporary enrollment pause until safety follow-up and dose-escalation guidance were stronger. Safety and pharmacovigilance, or PV, wanted no new participants exposed until case follow-up was complete enough to support a risk-benefit reassessment. Regulatory wanted a conservative authority communication posture. Quality wanted a corrective and preventive action, or CAPA, discussion for recurring handoff failures and consent-version drift. Biostatistics warned that a partial amendment could complicate endpoint interpretation. Finance warned that a pause would force a major reforecast. Clinical Operations worried that sites would lose momentum. Commercial wanted to avoid public signals of trouble. The contract research organization, or CRO, wanted clearer sponsor direction. Patient Engagement asked whether participants would trust the sponsor if they learned later that the team had debated risk quietly. Everyone was not wrong. That was the leadership problem. Leadership in a divided clinical trial room is not charisma. It is the discipline of helping accountable people make a defensible decision when evidence, values, authority, and risk do not line up neatly. Dr. Daniel Liang joined the governance meeting as President of Global Clinical Trial Management Department. He listened longer than Lauren expected. Then he said, "A divided room is not automatically a broken room. Sometimes it is the sound a serious decision makes before it becomes honest." ## The DIVIDE Frame Caroline Whitaker wrote the frame on the whiteboard: | Letter | Meaning | PM Question | |---|---|---| | D | Define The Decision | What exact decision must be made now? | | I | Identify The Irreducible Risks | What cannot be wished away by optimism or pressure? | | V | Voices And Authority | Who must be heard, and who has decision rights? | | I | Impact Of Each Option | What happens to participants, data, timeline, budget, regulators, and credibility? | | D | Document Rationale | Can the decision be reconstructed and defended later? | | E | Execute Without Ambiguity | What must happen immediately after the decision? | Governance is the structured way an organization makes and records decisions. A decision owner is the person or body authorized to decide. An accountable owner is the person responsible for the outcome or recommendation in a defined area. Decision rights clarify who recommends, who decides, who must be consulted, and who must be informed. Consensus means general agreement. Alignment means people understand and can support the decision, even when not everyone got the answer they preferred. Dissent is a meaningful disagreement or concern. Constructive dissent is not disloyalty. It is often how the organization protects participants, data integrity, regulatory credibility, and its own conscience. ## Define The Decision Before Debating Positions The first RESP-640 conversation sounded like this: "We should pause." "We cannot pause." "We need more data." "We need to tell sites now." "We should amend." "We should wait." Lauren had seen enough meetings to know that a room can argue for an hour before anyone names the decision. Caroline helped her write the decision statement: > Decision needed: Should RESP-640 continue enrollment unchanged, continue with enhanced safeguards, pause enrollment temporarily, pause dose escalation, narrow eligibility, proceed with amendment and consent updates, or stop part of the study while safety follow-up and regulatory/ethics communication continue? That sentence changed the discussion. It turned opinions into options. GI-520 gave Lauren a smaller but useful leadership rehearsal. The gastrointestinal pilot had only a limited footprint, yet the team split over whether to expand sites after slow screen-in. Rafael wanted broader access, Claire Jiang questioned whether the pilot would still answer its feasibility question, and Maya warned that expansion would consume the contingency reserve. Daniel asked Lauren to write the decision as one sentence before collecting opinions: "Are we preserving the pilot question, or converting the study into a larger operational rescue?" Once the decision was named, the debate became manageable. ONCO-CELL-901 created a higher-stakes version of the same discipline. Manufacturing-slot uncertainty, participant urgency, and site readiness did not fit neatly into a green/yellow/red dashboard. Daniel asked the team to separate patient-access urgency from operational readiness and to record who accepted each residual risk. | Conflict Type | What It Sounds Like | PM Response | |---|---|---| | Evidence disagreement | "We do not know enough yet." | Name knowns, unknowns, evidence owner, and due date | | Risk tolerance disagreement | "This is acceptable" versus "This is too risky" | Clarify residual risk and accepting authority | | Decision-rights confusion | "Who gets to decide this?" | Move to governance forum with defined authority | | Timeline/budget pressure | "We cannot

...